logo-loader

Medicus Pharma receives coverage from Stonegate Capital Partners

Published: 10:21 24 Sep 2025 EDT

Medicus Pharma - Medicus Pharma receives coverage from Stonegate Capital Partners

Medicus Pharma (NASDAQ:MDCX) announced that Stonegate Capital Partners has initiated coverage on the company. 

Stonegate analysts wrote that with the closing of its $8 million debenture financing, Medicus has cash of $9.7 million as of the second quarter of 2025, which extends the company’s runway into 2026. 

Stonegate also highlighted its acquisition of Antev Limited in Q2, which adds dermatology and infectious disease assets to the company, along with Medicus Pharma’s Memorandum of Understanding (MoU) with Helix Nanotechnologies to develop thermostable infectious disease vaccines. 

“Together, these programs position Medicus with a diversified pipeline targeting both near-term specialty indications and longer-term global opportunities," the analysts wrote.  

They added that Medicus Pharma management continues to pursue additional high-impact assets to complement this portfolio and leverage its multi-strategy model.  

Stonegate Capital analysts said their valuation model returns a valuation range of $14.91 to $29.35 with a midpoint of $21.13 based on a discount rate range of 17.50% to 22.50% and a current risk adjustment range of 50% to 40%. The shares are currently changing hands for $2.64.

 

Medicus Pharma shares rationale as CD228V becomes lead development priority

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug...

1 week, 2 days ago